Issue 3/2012
Content (16 Articles)
Antiangiogenic therapy in the management of brain tumors: a clinical overview
Saroj Kunnakkat, Maya Mathew, Ashwatha Narayana
Increased expression and function of P-glycoprotein in peripheral blood CD56+ cells is associated with the chemoresistance of non-small-cell lung cancer
Li Han, Ya Feng Wang, Yan Zhang, Ning Wang, Xiao Juan Guo, Jing Ke Yang, Kui Peng Wang, Su Na Liu, Qing Xia Fan, Ke Li, Jin Hua Jiang, Qing Duan Wang
Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment
Yumiko Aoyama, Tetsuya Nishimura, Taiji Sawamoto, Taroh Satoh, Masataka Katashima, Kazuhiko Nakagawa
Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer
Jae-Sung Kim, Joo Han Lim, Jee Hyun Kim, Seock-Ah Im, Eui Kyu Chie, Jin-Hyeok Hwang, Tae-You Kim, Yung-Jue Bang, Sung Whan Ha, Yong Bum Yoon
Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis
Yuki Kojima, Kenji Hashimoto, Masashi Ando, Kan Yonemori, Harukaze Yamamoto, Makoto Kodaira, Mayu Yunokawa, Chikako Shimizu, Kenji Tamura, Ako Hosono, Atsushi Makimoto, Yasuhiro Fujiwara
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
Yosuke Togashi, Katsuhiro Masago, Satohiro Masuda, Tomoyuki Mizuno, Masahide Fukudo, Yasuaki Ikemi, Yuichi Sakamori, Hiroki Nagai, Young Hak Kim, Toshiya Katsura, Michiaki Mishima
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors
Haruyasu Murakami, Toshihiko Doi, Nobuyuki Yamamoto, Junichiro Watanabe, Narikazu Boku, Nozomu Fuse, Takayuki Yoshino, Atsushi Ohtsu, Satoru Otani, Kazuhiro Shibayama, Takatoshi Takubo, Elwyn Loh
Anti-proliferative effect of 23,24-dihydrocucurbitacin F on human prostate cancer cells through induction of actin aggregation and cofilin-actin rod formation
Shuai Ren, Dong-Yun Ouyang, Mark Saltis, Li-Hui Xu, Qing-Bing Zha, Ji-Ye Cai, Xian-Hui He
Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways
Xiuxia Li, Xuewei Wang, Haoyu Ye, Aihua Peng, Lijuan Chen
Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates
Diego A. Gianolio, Cecile Rouleau, William E. Bauta, Dennis Lovett, William R. Cantrell Jr., Antonio Recio III, Paul Wolstenholme-Hogg, Michelle Busch, Peng Pan, James E. Stefano, Hildegard M. Kramer, James Goebel, Roy D. Krumbholz, Stephanie Roth, Steven M. Schmid, Beverly A. Teicher
Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis
Yasuyoshi Miyata, Koichiro Nomata, Kojiro Ohba, Tomohiro Matsuo, Yuji Sagara, Hiroshi Kanetake, Hideki Sakai
Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
Mike Dennis, Michelle Davies, Stuart Oliver, Roy D’Souza, Laura Pike, Paul Stockman
A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors
Suzanne F. Jones, Jeffrey R. Infante, Dana S. Thompson, Adil Mohyuddin, Johanna C. Bendell, Denise A. Yardley, Howard A. Burris III
AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts
Radhika Iyer, Carly R. Varela, Jane E. Minturn, Ruth Ho, Anisha M. Simpson, Jennifer E. Light, Audrey E. Evans, Huaqing Zhao, Kenneth Thress, Jeffrey L. Brown, Garrett M. Brodeur
Dose escalation and pharmacokinetic study of nanoparticle curcumin… by Kanai et al., CCP 69:65–70, 2012
Andreas J. Gescher
In response
Masashi Kanai, Shigemi Matsumoto, Yoshihiko Otsuka, Masafumi Fukuda, Atsushi Imaizumi